 |
| Professor Eric Morand |
Professor Morand leads clinical and
basic research in systematic erythematosus (SLE, or lupus) at the Monash Health
Translation Precinct. Professor Morand also established and leads
the Asia
Pacific Lupus Collaboration (APLC), a collaboration of expert lupus
clinicians and researchers from 21 centres, aiming to improve outcomes for
patients with the disease.
“Measuring patient outcomes, and understanding biological
variation in lupus has been historically highly problematic, leading to
difficulty in design of clinical trials and contributing in part to the failure
to develop major breakthrough new treatments,” Professor Morand said.
“Thanks to the APLC collaboration, we have developed a new way to
measure outcomes in Lupus clinical trials”.
Professor Morand also leads basic and
translational research into lupus, funded by NHMRC and prestigious
international awards. This work has resulted in research collaborations with several
international biotech and pharmaceutical companies, including CSL, Australia’s
largest biopharma company, and has raised more than $2M in industry
support for his research over the last five years.
In addition, his collaborative work with
other Monash and Hudson Institute researchers, on the biology of an anti-inflammatory
protein in lupus, including a new treatment approach, has led to a new Monash
spinoff company that aims to produce biological therapeutics for patients.
Head, Department of Medicine Professor
Peter Ebeling said Professor Morand’s major role in our partnerships with
Novartis and CSL have resulted in global level interactions that will bring
more enterprise engagement in the future.
“These have involved the promotion not of
Professor Morand’s own work but rather of Monash University at large,”
Professor Ebeling said.
No comments:
Post a Comment